Neurocrine kept at sell by Merrill

Merrill Lynch analyst Eric Ende maintained Neurocrine Bioscience Inc. at its sell rating on news that the company terminated its worldwide collaboration with Pfizer for indiplon. The analyst does not see Neurocrine as able to market the drug on its own and believes the drug would have sales of no more than $100 million. Shares of the San Diego-based pharmaceutical company were down $3.96, or 28.67%, at $9.85 on volume of 25,982,888 shares versus the three-month running average of 2,516,940 shares. (Nasdaq: NBIX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.